Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare has launched the next-generation bkActiv system, expanding its application into Urology, Colorectal, and Pelvic Floor surgeries. This advanced intraoperative ultrasound imaging system is designed to enhance surgeons' ability to visualize anatomical structures, offering exceptional control during procedures. Key features include automatic no-touch autogain and advanced algorithms for superior image quality, enabling confident, real-time surgical decision-making with minimal user interaction. The bkActiv’s new advancements include detailed imaging capabilities for prostate, kidney, and bladder surgeries, as well as sophisticated color Doppler technology. This launch is part of GE HealthCare's strategy to leverage its acquisition of BK Medical and expand its ultrasound offerings.
GE HealthCare reported a strong financial performance for Q1 2023, with revenues of $4.7 billion, an 8% increase year-over-year. Organic revenue growth reached 12%, significantly aided by improved supply chain fulfillment. Net income attributable to the company was $372 million, a decline from $389 million in Q1 2022. Diluted EPS fell to $0.41 from $0.86 in the previous year, primarily due to a noncontrolling interest redemption. However, Adjusted EBIT rose to $664 million, reflecting an increase in operational efficiency, while cash flow from operations remained steady at $468 million.
The board declared a dividend of $0.03 per share, and the company maintains its organic revenue growth guidance for 2023 between 5% to 7%.
GE HealthCare (Nasdaq: GEHC) has received US FDA 510(k) clearance for its CARESCAPE Canvas patient monitoring platform. This innovation enhances patient care with a unified, flexible, and scalable monitoring solution, designed to adapt to the individual needs of patients. The platform features smart parameter technology that supports various patient acuity levels, with a focus on ease of use and standardization. CARESCAPE Canvas has demonstrated significant sustainability improvements, including a 53% reduction in packaging volume and a 25% reduction in energy consumption compared to earlier models. The product was awarded the prestigious iF Design Award 2023 for its excellence in medical product design. It has been approved for usage in the EU since June 2022 and is now cleared for the US market.
GE HealthCare (Nasdaq: GEHC) has launched CT-Navigation, enhancing its precision care strategy by providing clinicians with real-time, 3D CT imaging for improved guidance during interventional procedures. This innovative technology allows for safer needle guidance, reducing radiation exposure and procedure time while improving patient outcomes. CT-Navigation simplifies intervention planning and offers real-time navigation, thus minimizing variability across procedures. Developed by IMACTIS, CT-Navigation is now part of GE HealthCare's portfolio following a recent acquisition and has received FDA clearance and EU Medical Devices Regulation approval. The company anticipates expanding this technology to its image-guided therapy business soon, increasing its market reach and clinical applications.
GE HealthCare (NASDAQ: GEHC) is set to showcase its innovative digital healthcare solutions at the HIMSS Global Health Conference in Chicago from April 17-21, 2023. Key products include Viewpoint 6, a scalable ultrasound IT solution, and ReadySee, an asset management and network supervision tool enhancing device monitoring and cybersecurity. The Portrait Mobile monitoring solution allows for wireless patient monitoring, while the MUSE Ecosystem integrates patient-acquired ECGs into existing workflows. GE HealthCare aims to improve patient care outcomes through its technology while advancing personalized and connected healthcare. The company operates an $18.3 billion enterprise with over 50,000 employees, committed to enhancing healthcare efficiency and patient experience.
GE HealthCare (Nasdaq: GEHC) is set to announce its first quarter 2023 financial results before the market opens on April 25, 2023. A conference call and webcast will be held at 8:00 a.m. Eastern Time on the same day, accessible through their Investor Relations website. GE HealthCare, a leader in medical technology and digital solutions, aims to enhance healthcare efficiency and patient outcomes. The company operates with a workforce of 50,000 employees and reported revenues of $18.3 billion. For more details, visit GE HealthCare's website.
GE HealthCare (Nasdaq: GEHC) has entered a strategic agreement with Advantus Health Partners worth up to $760M over 10 years. This collaboration aims to provide comprehensive Healthcare Technology Management (HTM) services to Advantus' clients, enhancing medical equipment maintenance beyond the traditional break-fix model. The initiative focuses on improving quality care while reducing costs through advanced asset management and proactive monitoring. The HTM program will include services like equipment recalls management and real-time location tracking, ultimately aiming for more efficient healthcare outcomes.
GE HealthCare has completed Phase I subject recruitment for a novel manganese-based macrocyclic MRI contrast agent. Announced at the European Congress of Radiology in Vienna, this investigational agent offers a potential alternative to traditional gadolinium-based agents, addressing concerns about gadolinium retention in the body. The clinical trial, led by Hasse K. Zaré at Oslo University Hospital, aims to assess its safety and elimination profile. Manganese, being naturally occurring in the body, ensures efficient excretion, positioning this agent as a promising addition to GE HealthCare's portfolio in precision imaging.
GE HealthCare has granted SonoThera exclusive global commercial licensing rights for its Optison® and Sonazoid® microbubble products. These products will aid the development of SonoThera’s innovative ultrasound-guided, nonviral gene therapy platform. The technology aims to non-invasively deliver diverse nucleic acid payloads to various organs, addressing significant delivery challenges in gene therapy. SonoThera is currently in preclinical development, preparing for Phase 1 clinical trials. Terms of the licensing agreement were not disclosed, but the collaboration underscores a shared commitment to improving patient outcomes.
GE HealthCare (Nasdaq: GEHC) announces that President and CEO Peter Arduini, along with Vice President and CFO Helmut Zodl, will present at two investor conferences in March 2023.
- Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023, at 12:30 pm ET in New York City.
- Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 am ET (virtual event).
Investors can access the events live on GE HealthCare’s Investor Relations website. GE HealthCare is a leading global innovator in medical technology and digital solutions, focused on improving patient care.